A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis
{{output}}
Denosumab, a fully human monoclonal antibody to RANK ligand [RANK-L]) was approved for the treatment of postmenopausal osteoporosis in June 2010, and is highly effective in reducing the risk of vertebral, nonvertebral, and hip fracture risk. The registration o... ...
